Respirion’s inhaled therapy for cystic fibrosis, RSP-1502, was featured on Nine News Perth this week.
We have initiated a Phase 2 study, at 21 sites in Australia and the US, which will evaluate the therapy in children and adults. Earlier trials conducted with the Telethon Kids Institute and WA Health showed improved bacterial clearance and lung function. Thank you to reporter Holly Edwards-Smith, as well as Emma and her mother, for courageously sharing their experience and bringing awareness to this important research.
